期刊
AMERICAN HEART JOURNAL
卷 241, 期 -, 页码 38-49出版社
MOSBY-ELSEVIER
DOI: 10.1016/j.ahj.2021.06.013
关键词
Angina; Angiogenesis; Coronary artery disease; Clinical trial; Gene therapy; Refractory angina
The EXACT trial aims to evaluate the safety and efficacy of XC001 gene therapy for patients with refractory angina. The study will monitor adverse events and physiological parameters over a 6-month period to assess the treatment's impact on exercise tolerance and myocardial perfusion, with the goal of informing future clinical research.
Background Patients with refractory angina (RA) have poor quality of life and new therapies are needed. XC001 is a novel adenoviral vector expressing multiple isoforms of vascular endothelial growth factor (VEGF) promoting an enhanced local angiogenic effect. Methods The Epicardial Delivery of XC001 Gene Therapy for Refractory A ngina Coronary Treatment (EXACT) trial is a 6-month (with 6-month extension) phase 1/2, first-in-human, multicenter, open-label, single-arm, dose-escalation study to evaluate the safety, tolerability, and preliminary efficacy of XC001 in patients with RA. The trial will enroll 33 patients in an initial (n = 12) ascending dose-escalation phase (1 x 10(9) , 1 x 10(10) , 4 x 10(10) , and 1 x 10(11) viral particles), followed by phase 2 (n = 21) assessing the highest tolerated dose. Patients must have stable Canadian Cardiovascular Society (CCS) class II-IV angina on maximally tolerated medical therapy without options for conventional revascularization, demonstrable ischemia on stress testing, and angina limiting exercise tolerance. XC001 will be delivered directly to ischemic myocardium via surgical transthoracic epi c ardial access. The primary outcome is safety via adverse event monitoring through 6 months. Efficacy assessments include difference from baseline to month 6 in time to 1 mm of ST segment depression, time to angina, and total exercise duration; myocardial blood flow at rest, and stress and coronary flow reserve by positron emission tomography; quality of life; CCS functional class; and angina frequency. Conclusions The EXACT trial will determine whether direct intramyocardial administration of XC001 in patients with RA is safe and evaluate its effect on exercise tolerance, myocardial perfusion, angina and physical activity, informing future clinical investigation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据